CAMP4 Therapeutics Corporation Common Stock (CAMP)

FairStock Score: 21/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett/Graham investor, I look first for durable earning power and a margin of safety. CAMP4 is a clinical-stage RNA company with no approved product and no profits. In fiscal 2025, the year ended 2025-12-31, revenue was just $3.5 million against a net loss of $80.4 million. In fiscal 2024, the year ended 2024-12-31, revenue was $652,000 and net loss $51.8 million; in fiscal 2023, the year ended 2023-12-31, revenue was $350,000 and net loss $49.3 million. More recently, in fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $1.8 million and net loss was $33.5 million. That is not a business I can value on earnings. FairStock's calculated free cash flow is negative $28.7 million over the trailing twelve months, a -13.3% FCF yield on the 2026-10-13 close. The Piotroski score of 2/9 and Altman Z-score of -3.33 suggest financial weakness. The low debt-to-equity of 0.07 is a comfort, but cash burn means future financing risk remains. Competitive moat? I see none yet; RNA therapeutics is crowded and success rests on clinical trials, not brand or switching costs. FairStock calculations put the P/E at -1.48 and P/B at 7.31 at the 2026-10-13 close, so price is not anchored to profits or book. FairStock score is 21/100. The computed Lynch category is none, because losses occurred in each of the last three years. Growth in revenue from a tiny base is encouraging, but losses are far larger. As Graham might say, this is speculation on pipeline outcomes, not investment with a margin of safety. I would need proof of durable cash generation or a much lower price relative to assets before calling it compelling.

In plain English: CAMP4 is a small drug company working on RNA medicines for genetic diseases, with its main drug still in early human testing. The business is not yet making a profit, revenue is tiny, and losses are large, so the current share price is not supported by today's sales or earnings. It looks like a high-risk, speculative stock rather than a cheap, proven business.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer